NCT01463774View on ClinicalTrials.gov

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Healthy

Interventions

DRUG

Treatment A: Canagliflozin tablet

Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.

DRUG

Treatment A: Metformin IR tablets

Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.

DRUG

Treatment B: Canagliflozin/metformin fixed dose combination tablets

Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.

Trial Locations (1)

Unknown

Lincoln

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01463774 - A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers | Biotech Hunter | Biotech Hunter